Oxford Therapeutics Limited

The Home of Behavioural Solutions for Sustainable Weight Loss

At Oxford Therapeutics Limited, we are dedicated to the development and delivery of evidence-based behaviour-change strategies in the weight-loss arena. Our work draws on over 15,000 hours of 1:1 clinical experience with insights gained from treating more than a thousand individuals navigating the challenges of long-term weight management.

The GLP-1 Exit Strategy, Publication date August 2025

The GLP-1 Exit Strategy is the essential guide for navigating the emotional, physical, and psychological challenges that follow GLP-1 treatment. As countless users are now learning, weight loss is only half the battle—maintenance is where the real work begins.

Drawing on decades of clinical experience, authors Martin and Marion Shirran—renowned for their pioneering work in obesity psychology and creators of Tactile Cognitive Behaviour Therapy (TCBT)—deliver a powerful, practical roadmap for post-medication success. Backed by science and rich with relatable case studies, The GLP-1 Exit Strategy is a toolkit for those transitioning from a course of GLP-1 medications.

Your Guide To Maintaining Weight Loss After Stopping The Jabs our new bookintroduce our latest resource:

The GLP-1 Exit Strategy has been written as an essential guide, a roadmap to help patients transition and navigate what comes after the medications stop. While the injections helped them lose the weight, we know it’s their mindset, habits, and strategy going forward that will ensure the weight loss achieved is permanent. The book is overflowing with proven, practical, real-world advice to help them maintain their transformation and thrive. The readers are not starting over; they are moving forward. Throughout the book, readers are additionally introduced to a group of individuals that are in the post GLP phase, and have successfully navigated the transition.

Award-Winning Programme

The Oxford Therapeutics weight-loss programme has gained the interest of healthcare professionals seeking a proven behaviour change, diet/exercise programme for their patients, to partner with their prescribing of GLP-1 receptor agonists. The programme introduces weight-loss patients to a holistic approach, addressing both psychological and behavioural aspects. It is widely accepted that the introduction of such a behaviour change, diet/exercise programme is a vital component in patients’ weight-loss journey.

Food and Drug Administration

In the United States, the Food and Drug Administration (FDA) has mandated that GLP-1 receptor agonist weight-loss medications be prescribed in conjunction with a behavioural change programme. The FDA’s approach aims to ensure that patients not only lose weight but also adopt healthier lifestyle habits, which is crucial for maintaining their weight loss in the long term. This regulatory stance underscores the necessity of a comprehensive treatment plan, as detailed on the pages of this website.

NICE

Similarly, the National Institute for Health and Care Excellence (NICE) in the United Kingdom advocates a multifaceted approach to weight management. NICE recommends that weight-loss medications be integrated into a comprehensive weight management programme. The guidance from NICE emphasises the importance of addressing obesity through a holistic and sustainable approach, aiming to deliver long-term health benefits and improved quality of life for patients. Marion Shirran, the co-founder of Oxford Therapeutics Ltd, is a NICE stakeholder and a member of the All-Party Parliamentary Group on Obesity.

A Seamless Solution

The innovative weight-loss programme stands out as a potential solution in weight management, combining clinical expertise with comprehensive behavioural change interventions incorporating diet and exercise recommendations. Consequently, it is well-positioned to seamlessly assist doctors in their endeavours to help patients achieve and maintain realistic weight-loss goals while promoting a healthier and more sustainable lifestyle. On the following pages, we provide details of the extensive, downloadable programme, and the partnership options available to Healthcare Professionals.

Oxford Therapeutics

Martin and Marion Shirran, the founders of Oxford Therapeutics, were responsible for developing the upgrade to the traditional Cognitive Behaviour Therapy (CBT) approaches and techniques. It’s known as Tactile Cognitive Behaviour Therapy, or TCBT. “In a single moment, you have elevated CBT from being a completely passive therapy into a useful tactile alternative!” (Dr Theano Kalavana). Academics, including Professor Windy Dryden, of Goldsmiths University London, and Professor Philip Zimbardo, of Stanford University, in San Francisco, have endorsed the therapy. Professor Zimbardo wrote the foreword to our book about TCBT, published by Hay House.

Following the growing use of the programme by orthopaedic surgeons, seeking reliable, pre-surgery, weight-loss interventions for their hip and knee replacement patients, doctors are now considering it as a potential component/partner, when prescribing GLP-1 receptor agonists.

---

---

Stakeholder in NICE – National Institute for Health and Care Excellence

Marion Shirran, as a director of Oxford Therapeutics Limited, is a registered Stakeholder in NICE – National Institute for Health and Care Excellence.

---

All-Party Parliamentary Group on Obesity

Marion is proud to be a member of the All-Party Parliamentary Group on Obesity.

---

Please visit the contact page for email or telephone details.